Molbio Diagnostics, one of India’s leading healthcare companies in the in-vitro diagnostics segment, launched a new manufacturing unit for its innovative molecular diagnostic platform - Truenat Real-Time PCR, spread across 1,35,000 Sq.ft, in Verna, Goa.

The new manufacturing unit was launched in the backdrop of increasing demand for point-of-care molecular testing, in India and across the world, to meet the critical need for reliable technologies that can enable early and accurate diagnosis. The new facility will increase the existing production capacity to 3.5 lakh units per day, thus strengthening indigenous production capacity and ensuring the uninterrupted availability of Truenat test kits.

Sriram Natarajan, director & CEO of Molbio Diagnostics, said, “This is a momentous occasion for us at Molbio. For the past year, our Truenat machines have been at the forefront of the fight against Covid-19. It has also been a gamechanger for tuberculosis and other diseases. The demand for high-quality, point-of-care molecular diagnostic systems is higher than ever today. With this new plant, the production of Truenat kits has increased five times, from 70,000 tests per day to 3.5 lakh tests per day. The technology of Truenat will have serious implications for point of care testing in India, and the world.”

Truenat testing kits are globally recognised as a true point-of-care molecular diagnostic platform that can test multiple diseases. Truenat Real-Time Quantitative micro PCR System is a multi-disease platform and can test over 30 diseases. This revolutionary technology has helped in reducing the spread of various infectious diseases like Covid-19, tuberculosis, dengue and more.